A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2018
Price : $35 *
At a glance
- Drugs Aglatimagene besadenovec (Primary) ; Valaciclovir
- Indications Malignant pleural effusion
- Focus Adverse reactions
- Acronyms MpeTK01
- Sponsors Advantagene
- 18 Oct 2017 Results assessing safety presented at the 18th World Conference on Lung Cancer.
- 07 Jun 2016 Results assessing safety of AdV-tk theray presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 28 Oct 2015 Planned End Date changed from 1 Oct 2016 to 1 Oct 2020 as reported by ClinicalTrials.gov.